Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Lonza to make COVID-19 antibody combination for AstraZeneca

FILE PHOTO: Swiss pharmaceutical group Lonza Houston, the world’s largest dedicated cell and gene therapy facility, opened on Tuesday in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer

Lonza Group has agreed with AstraZeneca to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, the Swiss contract manufacturer said on Friday.

AZD7442 is in Phase I clinical studies and AstraZeneca plans to advance the combination into Phase III trials in the coming weeks, Lonza said. Lonza will manufacture drug substance for AZD7442 at Lonza's facilities in the United States. Operations are expected to start in the first half of 2021.

(Reporting by Michael Shields; editing by Thomas Seythal)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.